Product image of Modiwart (Imiquimod) supplied by GNH India

Modiwart

Active Ingredient:
Imiquimod
Origin:
EU

Modiwart (Imiquimod)

Imiquimod, the active ingredient in Modiwart, is a immune response modifier presented as a unknown/unknown for topical (cutaneous) use. It treats actinic keratosis, superficial basal cell carcinoma and external genital warts in appropriate patients.

GNH India supplies Modiwart as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Iasis Pharma

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Imiquimod is indicated for skin conditions that benefit from a localized immune response.
  • Actinic keratosis: promotes clearance of precancerous lesions on sun‑damaged skin.
  • Superficial basal cell carcinoma: induces tumor regression in early‑stage skin cancer.
  • External genital warts: stimulates antiviral immunity to eliminate HPV‑related lesions.

How It Works

  • Imiquimod activates Toll‑like receptor 7 (TLR7) on dendritic cells and macrophages, leading to the production of cytokines such as interferon‑α, interleukin‑12 and tumor necrosis factor‑α. This cytokine cascade enhances both innate and adaptive immune responses, producing antiviral and antitumor activity at the site of application.

Side Effects

Imiquimod may cause a range of skin reactions, from mild irritation to severe inflammation.

Common Side Effects

  • Erythema: redness at the application site.
  • Pruritus: itching or mild discomfort.
  • Burning sensation: transient heat feeling.
  • Pain: localized soreness.
  • Crusting or scaling: formation of dry patches.
  • Swelling: mild edema around treated area.

Serious or Rare Side Effects

  • Severe contact dermatitis: extensive rash with blistering.
  • Exfoliative dermatitis: widespread skin shedding.
  • Systemic flu‑like symptoms: fever, chills, malaise.
  • Lymphadenopathy: swollen lymph nodes near the treated region.
  • Hypersensitivity reaction: urticaria or angioedema.
  • Secondary infection: bacterial overgrowth at irritated sites.

Precautions & Warnings

  • When prescribing Modiwart, clinicians should consider several safety measures.
  • Assess skin condition: ensure lesions are appropriate for topical immunotherapy.
  • Avoid application on broken skin: do not apply to open wounds or ulcerated areas.
  • Monitor for excessive inflammation: discontinue if severe redness or ulceration occurs.
  • Avoid concurrent use with other topical irritants: limit combination with harsh chemicals.
  • Pregnancy and lactation: consult a healthcare professional before use.
  • Store at room temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Imiquimod can interact with other agents that affect skin immunity or irritation.

Major Interactions (Avoid)

  • Concurrent use with other immune‑modulating topicals: may increase local irritation.
  • Systemic immunosuppressants (e.g., corticosteroids, biologics): may reduce therapeutic efficacy.

Moderate Interactions (Monitor Closely)

  • Topical corticosteroids: may diminish Imiquimod’s immune response.
  • Phototherapy or UV exposure: may heighten skin sensitivity.
  • Live vaccines: theoretical risk of altered immune response.
  • Antiviral creams containing acyclovir: may interfere with antiviral activity.
  • Herbal skin preparations: monitor for additive irritation.

Frequently Asked Questions

Modiwart contains Imiquimod and is used to treat actinic keratosis, superficial basal cell carcinoma, and external genital warts. It works by stimulating a local immune response that helps clear precancerous lesions, early skin cancers, and human papillomavirus (HPV)–related warts.

Imiquimod activates Toll‑like receptor 7 on immune cells, triggering the release of cytokines such as interferon‑α, interleukin‑12 and tumor necrosis factor‑α. This cascade enhances both innate and adaptive immunity, producing antiviral and antitumor effects directly at the site of application.

The dosing regimen for Modiwart is determined by the prescribing healthcare professional based on the specific indication, lesion size, and patient factors. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

Safety data for Imiquimod during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Modiwart, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The primary alternative for genital warts is podophyllotoxin, a cytotoxic agent, while 5‑fluorouracil is often used for actinic keratosis. Unlike these agents, Imiquimod works by enhancing the immune response rather than directly killing cells, which can result in a different side‑effect profile and may be preferred for patients who need a non‑cytotoxic approach.

Modiwart should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Modiwart is applied topically to the affected skin area. The prescribed amount is spread thinly on clean, dry skin, usually once daily or as directed by the prescriber, and left on the skin for the specified period before washing off if required.

Serious risks include severe local skin reactions such as extensive dermatitis, ulceration, or secondary infection, as well as systemic flu‑like symptoms. Patients should seek immediate medical attention if they experience intense pain, spreading rash, fever, or signs of an allergic reaction.

Modiwart should not be used by individuals with known hypersensitivity to Imiquimod or any excipients in the formulation. It is also contraindicated on broken or ulcerated skin, and caution is advised in patients with compromised immune systems or those receiving systemic immunosuppressive therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Imiquimod

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT